NCT00237861CompletedPhase 4
Effectiveness of Atypical Vs Conventional Antipsychotics
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Yale University
- Primary Endpoint
- PANSS
Study Overview
Brief Summary
This study will compare the effectiveness of newer atypical antipsychotics versus older conventional antipsychotics in treating schizophrenia.
Detailed Description
At seven participating hospitals, acutely exacerbated patients with schizophrenia were randomly assigned to treatment with antipsychotic from the atypical class vs antipsychotic from the conventional class. Medication choice within class, dose, concomitant medications, and other prescribing decisions were left to the community prescriber. Patients were followed for one year after discharge.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •hospitalized for schizophrenia
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
PANSS
Retention.
Secondary Outcomes
- EPS, TD.
Investigators
Similar Trials
Completed
Phase 4
Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in SchizophreniaSchizophreniaNCT01164059University of Bremen149
Completed
Phase 4
Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia NervosaEating DisordersNCT00685334New York State Psychiatric Institute22
Completed
Not Applicable
A Comparative Study of New Medications for Psychosis in AdolescentsPsychotic DisordersSchizophreniform DisordersSchizoaffective DisordersSchizophreniaNCT00222495University of Minnesota30
Unknown
Not Applicable
Antipsychotic to Treat Psychosis SyndromePsychotic DisordersNCT02137616Central South University300
Terminated
Phase 4
A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy ControlsSchizophreniaNCT00934635Janssen-Cilag G.m.b.H2